+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Hand, Foot and Mouth Disease - Pipeline Review, H1 2020

  • ID: 5017434
  • Drug Pipelines
  • March 2020
  • Region: Global
  • 46 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Adimmune Corp
  • CJ HealthCare Corp
  • Emergex Vaccines Ltd
  • MORE
Hand, Foot and Mouth Disease - Pipeline Review, H1 2020

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Hand, Foot and Mouth Disease - Pipeline Review, H1 2020, provides an overview of the Hand, Foot and Mouth Disease (Infectious Disease) pipeline landscape.

Hand, foot and mouth disease is an illness that causes sores in or on the mouth and on the hands, feet, and legs. Hand, foot and mouth disease (HFMD) is most commonly caused by coxsackievirus A16, a member of the enterovirus family. Symptoms include fever, headache, loss of appetite and ulcers in the throat (including tonsils), mouth, and tongue. Treatment includes antibiotics and pain relievers.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Hand, Foot and Mouth Disease - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Hand, Foot and Mouth Disease (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hand, Foot and Mouth Disease (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Hand, Foot and Mouth Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 3, 1, 4 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 4 and 2 molecules, respectively.

Hand, Foot and Mouth Disease (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hand, Foot and Mouth Disease (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Hand, Foot and Mouth Disease (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hand, Foot and Mouth Disease (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hand, Foot and Mouth Disease (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hand, Foot and Mouth Disease (Infectious Disease)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hand, Foot and Mouth Disease (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hand, Foot and Mouth Disease (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Adimmune Corp
  • CJ HealthCare Corp
  • Emergex Vaccines Ltd
  • MORE
  • Introduction
  • Report Coverage
  • Hand, Foot and Mouth Disease - Overview
  • Hand, Foot and Mouth Disease - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Hand, Foot and Mouth Disease - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Hand, Foot and Mouth Disease - Companies Involved in Therapeutics Development
  • Adimmune Corp
  • Beijing Minhai Biotechnology Co Ltd
  • Changchun Bcht Biotechnology Co Ltd
  • Chongqing Zhifei Biological Products Co Ltd
  • CJ HealthCare Corp
  • Emergex Vaccines Ltd
  • Sentinext Therapeutics Sdn Bhd
  • Shanghai Zerun Biotechnology Co Ltd
  • Takeda Pharmaceutical Co Ltd
  • Hand, Foot and Mouth Disease - Drug Profiles
  • (coxsackievirus [serotype A16] + enterovirus [serotype 71]) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • B-1108 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CJ-40010 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • D-5 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • DC-07090 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • E-71 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • enterovirus [serotype 71] (virus like particle) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Enterovirus [serotype EV-71/C4] vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Enterovirus [serotype EV-A71] (virus like particle, bivalent) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Enterovirus [serotype EV-A71] vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • hand, foot and mouth disease (bivalent) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • hand, foot and mouth disease vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Monoclonal Antibody for Hand, Foot and Mouth Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit MAP2K1 for Hand, Foot and Mouth Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • STX-100 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TAK-021 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Hand, Foot and Mouth Disease - Dormant Projects
  • Hand, Foot and Mouth Disease - Product Development Milestones
  • Featured News & Press Releases
  • Mar 11, 2012: Inviragen Reports Top-Line Results From Phase I Trial Of INV21 Vaccine For Treatment Of Hand, Foot And Mouth Disease
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
List of Tables
  • Number of Products under Development for Hand, Foot and Mouth Disease, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Hand, Foot and Mouth Disease - Pipeline by Adimmune Corp, H1 2020
  • Hand, Foot and Mouth Disease - Pipeline by Beijing Minhai Biotechnology Co Ltd, H1 2020
  • Hand, Foot and Mouth Disease - Pipeline by Changchun Bcht Biotechnology Co Ltd, H1 2020
  • Hand, Foot and Mouth Disease - Pipeline by Chongqing Zhifei Biological Products Co Ltd, H1 2020
  • Hand, Foot and Mouth Disease - Pipeline by CJ HealthCare Corp, H1 2020
  • Hand, Foot and Mouth Disease - Pipeline by Emergex Vaccines Ltd, H1 2020
  • Hand, Foot and Mouth Disease - Pipeline by Sentinext Therapeutics Sdn Bhd, H1 2020
  • Hand, Foot and Mouth Disease - Pipeline by Shanghai Zerun Biotechnology Co Ltd, H1 2020
  • Hand, Foot and Mouth Disease - Pipeline by Takeda Pharmaceutical Co Ltd, H1 2020
  • Hand, Foot and Mouth Disease - Dormant Projects, H1 2020
List of Figures
  • Number of Products under Development for Hand, Foot and Mouth Disease, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Targets, H1 2020
  • Number of Products by Stage and Targets, H1 2020
  • Number of Products by Mechanism of Actions, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Adimmune Corp
  • Beijing Minhai Biotechnology Co Ltd
  • Changchun Bcht Biotechnology Co Ltd
  • Chongqing Zhifei Biological Products Co Ltd
  • CJ HealthCare Corp
  • Emergex Vaccines Ltd
  • Sentinext Therapeutics Sdn Bhd
  • Shanghai Zerun Biotechnology Co Ltd
  • Takeda Pharmaceutical Co Ltd
Note: Product cover images may vary from those shown
Adroll
adroll